EP1844006A2 - Taurinsynthese-herstellung und -verwendung als medizin - Google Patents
Taurinsynthese-herstellung und -verwendung als medizinInfo
- Publication number
- EP1844006A2 EP1844006A2 EP05818935A EP05818935A EP1844006A2 EP 1844006 A2 EP1844006 A2 EP 1844006A2 EP 05818935 A EP05818935 A EP 05818935A EP 05818935 A EP05818935 A EP 05818935A EP 1844006 A2 EP1844006 A2 EP 1844006A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- effective
- concentrations
- prevention
- combinations
- controlling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 title claims abstract description 41
- 229960003080 taurine Drugs 0.000 title claims abstract description 20
- 230000015572 biosynthetic process Effects 0.000 title abstract description 5
- 239000003814 drug Substances 0.000 title description 3
- 238000004519 manufacturing process Methods 0.000 title description 2
- 238000003786 synthesis reaction Methods 0.000 title description 2
- 239000002253 acid Substances 0.000 claims abstract description 9
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims abstract description 3
- 230000002265 prevention Effects 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 150000002632 lipids Chemical class 0.000 claims description 5
- 229940088594 vitamin Drugs 0.000 claims description 5
- 229930003231 vitamin Natural products 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 239000011782 vitamin Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 208000004930 Fatty Liver Diseases 0.000 claims description 4
- 208000012902 Nervous system disease Diseases 0.000 claims description 4
- 206010008635 Cholestasis Diseases 0.000 claims description 3
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 3
- 108090001030 Lipoproteins Proteins 0.000 claims description 3
- 102000004895 Lipoproteins Human genes 0.000 claims description 3
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 claims description 3
- 229960004308 acetylcysteine Drugs 0.000 claims description 3
- 230000007870 cholestasis Effects 0.000 claims description 3
- 231100000359 cholestasis Toxicity 0.000 claims description 3
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 claims description 3
- 108020004511 Recombinant DNA Proteins 0.000 claims description 2
- 150000001447 alkali salts Chemical class 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 201000001883 cholelithiasis Diseases 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 235000019441 ethanol Nutrition 0.000 claims description 2
- 208000010706 fatty liver disease Diseases 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000006041 probiotic Substances 0.000 claims description 2
- 235000018291 probiotics Nutrition 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 12
- 235000012000 cholesterol Nutrition 0.000 abstract description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract description 4
- 239000003833 bile salt Substances 0.000 abstract description 4
- 229940093761 bile salts Drugs 0.000 abstract description 4
- 230000037361 pathway Effects 0.000 abstract description 3
- 239000004471 Glycine Substances 0.000 abstract description 2
- 241000124008 Mammalia Species 0.000 abstract description 2
- 239000003613 bile acid Substances 0.000 abstract description 2
- 230000029142 excretion Effects 0.000 abstract description 2
- 239000003529 anticholesteremic agent Substances 0.000 abstract 1
- 229940127226 anticholesterol agent Drugs 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000005229 liver cell Anatomy 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 description 5
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 3
- 239000004380 Cholic acid Substances 0.000 description 3
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 3
- 229960002471 cholic acid Drugs 0.000 description 3
- 235000019416 cholic acid Nutrition 0.000 description 3
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 238000002245 gallstone dissolution Methods 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
- C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
- C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
Definitions
- bile salts the conjugate bases of bile acids.
- the major bile salts are synthesized and secreted by as glycine or taurine conjugates.
- Taurine is a degradation product of cysteine. Taurine (2-aminoethyl sulphonic acid) is a component of bile. It combines with cholic acid to form taurocholic acid. Cholic acid is the metabolic fate of cholesterol. The formation of cholic acid involves a pathway involving several hydroxylations and oxidation reactions. All water soluble vitamins participate in these reactions.
- Taurine lowers cholesterol, and this action is potentiated by the presence of water soluble vitamins.
- Taurine is effective in lowering hypercholesterolaemia, hypertriglyceridaemia and all lipid associated disorders as in cholestasis or nephrotic syndrome, etc.. also it is effective in any type of familial or idiopathic or acquired lipid disorder. Taurine is cardioprotective. ( Taurine is also effective in gall stone dissolution.
- Taurine is safe, and effective in normalizing high cholesterol, low density lipoproteins, or very low density lipoproteins.
- Taurine is also essential for stabilizing brain cells against changes in blood osmolality, and in conversion of serotonin to endorphins. It is effective in depression, migraine, headache, Alzheimer disease, and in psychiatric and neurological diseases.
- lipids, lipoproteins, cholesterol, and hypercholestrolaemia associated diseases, psychiatric and neurological diseases and in gall stone dissolution the following singly or combined are effective: a. Taurine b. Cysteine and/or acetyl cysteine, c. All water soluble vitamins.
- the "a”, or “b” or “c” or as “a+b”, or “a+c”, or “b+c” or, “a+ b+ c” in any and all concentrations and combinations are effective in prevention and controlling all hypercholestrolaemias, hypertriglycerdaemias, and all and any lipid and lipoprotein disorders.
- the “a”, or “b” or “c” or as “a+b”, or “a+c”, or “b+c” or, “a+ b+ c” in any and all concentrations and combinations are effective in prevention and controlling cholestasis disorders of any aetiology. viii.
- the "a”, or “b” or “c” or as “a+b”, or “a+c”, or “b+c” or, “a+ b+ c” in any and all concentrations and combinations are effective in prevention and controlling steatosis of liver and steatohepatitis disorders of any aetiology.
- the “a”, or “b” or “c” or as “a+b”, or “a+c”, or “b+c” or, “a+ b+ c” in any and all concentrations and combinations are effective in prevention, dissolution and controlling gall stone diseases.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EG2005010013 | 2005-01-05 | ||
| PCT/EG2005/000044 WO2006072259A2 (en) | 2005-01-05 | 2005-12-31 | Taurine synthesis, production and utility as a medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1844006A2 true EP1844006A2 (de) | 2007-10-17 |
Family
ID=36647837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP05818935A Withdrawn EP1844006A2 (de) | 2005-01-05 | 2005-12-31 | Taurinsynthese-herstellung und -verwendung als medizin |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1844006A2 (de) |
| JP (1) | JP2008526789A (de) |
| KR (1) | KR20070091198A (de) |
| CN (1) | CN101146767A (de) |
| AP (1) | AP2007004084A0 (de) |
| AU (1) | AU2005324199A1 (de) |
| BR (1) | BRPI0519606A2 (de) |
| CA (1) | CA2593563A1 (de) |
| EA (1) | EA200701434A1 (de) |
| IL (1) | IL184221A0 (de) |
| MA (1) | MA29238B1 (de) |
| MX (1) | MX2007008196A (de) |
| NO (1) | NO20074937A (de) |
| TN (1) | TNSN07226A1 (de) |
| WO (1) | WO2006072259A2 (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20130590T1 (en) | 2007-11-30 | 2013-08-31 | The Regents Of The University Of California | Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products |
| CN103382170B (zh) * | 2012-10-25 | 2015-04-08 | 潜江永安药业股份有限公司 | 一种牛磺酸的制备方法 |
| CN106728405A (zh) * | 2016-11-15 | 2017-05-31 | 陈思文 | 一种牛磺酸和水溶性茶多酚复方组合物及其制备方法与应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58140017A (ja) * | 1981-12-22 | 1983-08-19 | Junichi Azuma | 心不全治療剤 |
| JPH08208464A (ja) * | 1994-12-02 | 1996-08-13 | Taisho Pharmaceut Co Ltd | 高脂血症の治療及び予防薬 |
| US6184227B1 (en) * | 1995-07-21 | 2001-02-06 | Savvipharm Inc. | Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases |
| SE9601395D0 (sv) * | 1996-04-12 | 1996-04-12 | Dieter Haeussinger | New therapeutic treatment 1 |
| GB9722361D0 (en) * | 1997-10-24 | 1997-12-17 | Pharma Nord Uk Ltd | Pharmaceutical formulation for treating liver disorders |
| NZ527924A (en) * | 1999-01-29 | 2005-01-28 | Mars Uk Ltd | Antioxidant compositions and methods for companion animals |
| AU8003800A (en) * | 1999-10-08 | 2001-04-23 | Joyce Corinne Bechthold | Methods and compositions for treating neurobehavioral disorders |
| CN1340502A (zh) * | 2000-06-30 | 2002-03-20 | 张永春 | 牛磺酸合锌的生产工艺 |
| CN1268733C (zh) * | 2004-07-20 | 2006-08-09 | 刘辉 | 牛磺酸功能啤酒及其生产工艺 |
-
2005
- 2005-12-31 EP EP05818935A patent/EP1844006A2/de not_active Withdrawn
- 2005-12-31 MX MX2007008196A patent/MX2007008196A/es not_active Application Discontinuation
- 2005-12-31 CN CNA2005800460663A patent/CN101146767A/zh active Pending
- 2005-12-31 WO PCT/EG2005/000044 patent/WO2006072259A2/en not_active Ceased
- 2005-12-31 BR BRPI0519606-0A patent/BRPI0519606A2/pt not_active IP Right Cessation
- 2005-12-31 CA CA002593563A patent/CA2593563A1/en not_active Abandoned
- 2005-12-31 AP AP2007004084A patent/AP2007004084A0/xx unknown
- 2005-12-31 EA EA200701434A patent/EA200701434A1/ru unknown
- 2005-12-31 AU AU2005324199A patent/AU2005324199A1/en not_active Abandoned
- 2005-12-31 KR KR1020077016443A patent/KR20070091198A/ko not_active Withdrawn
- 2005-12-31 JP JP2007549796A patent/JP2008526789A/ja active Pending
-
2007
- 2007-06-14 TN TNP2007000226A patent/TNSN07226A1/fr unknown
- 2007-06-26 IL IL184221A patent/IL184221A0/en unknown
- 2007-07-26 MA MA30110A patent/MA29238B1/fr unknown
- 2007-09-28 NO NO20074937A patent/NO20074937A/no not_active Application Discontinuation
Non-Patent Citations (1)
| Title |
|---|
| See references of WO2006072259A3 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101146767A (zh) | 2008-03-19 |
| KR20070091198A (ko) | 2007-09-07 |
| AP2007004084A0 (en) | 2007-08-31 |
| CA2593563A1 (en) | 2006-07-13 |
| EA200701434A1 (ru) | 2008-10-30 |
| WO2006072259A2 (en) | 2006-07-13 |
| MX2007008196A (es) | 2008-02-22 |
| JP2008526789A (ja) | 2008-07-24 |
| TNSN07226A1 (en) | 2008-11-21 |
| BRPI0519606A2 (pt) | 2009-02-25 |
| NO20074937A (no) | 2007-09-28 |
| MA29238B1 (fr) | 2008-02-01 |
| IL184221A0 (en) | 2008-12-29 |
| AU2005324199A1 (en) | 2006-07-13 |
| WO2006072259A3 (en) | 2007-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW589186B (en) | Ascorbyl-phosphoryl-cholesterol | |
| IE53432B1 (en) | A method for preparing ganglioside derivatives and use thereof in pharmaceutical compositions | |
| CN101098879B (zh) | 新的硒羟酸和衍生物以及在营养品、化妆品和药物中的应用 | |
| JP2014185163A (ja) | 同位体で置換されたリジンを用いたがん治療 | |
| EP0631779A1 (de) | Verwendung von L-carnitin- und Acyl-L-cernitinestern mit Hydroxysäuren zur Herstellung pharmazeutischer Zusammensetzungen zur Behandlung der Dermatosen | |
| CN111971290A (zh) | 用于预防或治疗关节疾病的葡萄糖胺衍生物 | |
| JP2002533421A (ja) | Ｎａａｌａｄアーゼ阻害因子を用いる疾患処置法 | |
| JPWO2005033123A1 (ja) | 安定なビタミンｂ６誘導体 | |
| EP4678629A1 (de) | Ionisierbares lipidmolekül, herstellungsverfahren dafür und verwendung davon | |
| EP1844006A2 (de) | Taurinsynthese-herstellung und -verwendung als medizin | |
| JP5671483B2 (ja) | 色素沈着予防又は改善剤 | |
| CA3202047A1 (en) | Fucosyltransferase specific inhibition using fucose mimetics | |
| CN120659771A (zh) | 一种氨基脂质化合物、其制备方法和应用 | |
| US6451761B1 (en) | N′N′-dichlorinated omega-amino acids and uses thereof | |
| FR2989087A1 (fr) | Nouveaux composes oligosaccharides et leur utilisation cosmetique | |
| JP2020514307A (ja) | 化合物及び使用方法 | |
| FR2894968A1 (fr) | Nouveaux derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation | |
| EP2072494B1 (de) | Kosmetische und pharmazeutische Zusammensetzungen | |
| WO2011030727A1 (ja) | パンテチンリン酸エステルを含む外用剤 | |
| EP1234816B1 (de) | Scyphostatin-Analoga als SMase-Inhibitoren | |
| CN109320577B (zh) | 具有抗肿瘤活性的夫西地酸衍生物及其合成制备方法 | |
| KR20030003952A (ko) | 염증성 피부질환의 예방 및 치료용 조성물 | |
| CN105102466B (zh) | 作为bace-1的抑制剂的糖树枝状簇化合物 | |
| US20160228489A1 (en) | Pharmaceutical composition for the prevention and the treatment of degenerative skin disorders especially caused by ionizing radiations | |
| CA3165408C (fr) | Dendrimeres a motifs thiophosphoramidate et derives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20070731 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL BA HR MK YU |
|
| R17D | Deferred search report published (corrected) |
Effective date: 20071004 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1103070 Country of ref document: HK |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1105119 Country of ref document: HK |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 9/10 20060101ALI20080128BHEP Ipc: A61K 31/145 20060101ALI20080128BHEP Ipc: C07C 303/02 20060101AFI20060720BHEP |
|
| DAX | Request for extension of the european patent (deleted) | ||
| 17Q | First examination report despatched |
Effective date: 20080623 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20081103 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1103070 Country of ref document: HK |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1105119 Country of ref document: HK |